cbmtg 0801 moving forward …
DESCRIPTION
CBMTG 0801 Moving Forward …. Activation Timeline. Canadian Sites. Projected Accrual. Site Activation. IRB approval Regulatory Documents (Checklist) Centre criteria for myeloablative and RIC HPCT SOP for transplant decision Site Agreement signed Site Initiation (Web conference). Consent. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/1.jpg)
CBMTG 0801Moving Forward …
![Page 2: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/2.jpg)
Activation Timeline
![Page 3: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/3.jpg)
Canadian Sites
![Page 4: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/4.jpg)
Projected Accrual
![Page 5: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/5.jpg)
Site Activation
• IRB approval
• Regulatory Documents (Checklist)Centre criteria for myeloablative and RIC HPCTSOP for transplant decision
• Site Agreement signed
• Site Initiation (Web conference)
![Page 6: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/6.jpg)
Consent
• Within 60 days of transplant
• French and English templates
• Verbal translation -- if ok with local REB
![Page 7: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/7.jpg)
Thymoglobulin in Unrelated Transplant
CBMTG 0801
If you will be undergoing a transplant from an unrelated donor for blood cancer, then you may be eligible for this trial.
This trial involves the addition of a drug called Thymoglobulin to the conditioning regimen prior to transplant.
![Page 8: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/8.jpg)
Screening Period
• Day -60 to Day -8
• Study procedures – standard work-up (except for study questionnaires)
• Health Canada guidelines for IDM’s
• Questionnaires to be completed prior to start of conditioning
![Page 9: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/9.jpg)
Randomization• All I & E must be met
• Randomize no earlier than 14 days prior to start of the preparative regimen
• Can be randomized up until 1 day prior to start of preparative
• Fax or email pdf to: Data Management Office (Vancouver)
![Page 10: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/10.jpg)
![Page 11: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/11.jpg)
Study Procedures – Post HPCT
Immune Reconstitution
![Page 12: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/12.jpg)
QOL, Chronic GVHD Follow-Up & HE
![Page 13: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/13.jpg)
Project Website
![Page 14: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/14.jpg)
http://cbmtg0801.org
![Page 15: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/15.jpg)
Study Tools
• Procedures spreadsheet
• Participant Information Pamphlet (in development)
• Days post transplant calculator
![Page 16: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/16.jpg)
Study Schedule
![Page 17: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/17.jpg)
![Page 18: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/18.jpg)
Data Collection
• Case report form posted on website (soon)
• Forms due within 1 month of time point
• Data locks q 6 months
![Page 19: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/19.jpg)
AE/SAE Reporting• AE’s grade 3 or greater to day 30
• CTCAE version 3.0
• Day 31 to 24 months – SAE’s only
• Report to DM Office within 24 hours (DM will report to Health Canada and
Genzyme)
• DSMC meets twice/year and as needed
![Page 20: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/20.jpg)
Infections• All grade 4 and 5 infections will be recorded in
the Data Collection Forms (and reported as SAEs)
• Additional information:Type of organism (suspected or documented); Activation of CMV requiring treatmentActivation of EBV either with symptoms or requiring
treatmentPrimary organ involved
![Page 21: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/21.jpg)
Centre Funding
• CENTRE FUNDING (CIHR) Per Patient Entered: $4000
• THYMOGLOBULIN: Order by centre, reimburse ($3900 per patient )
• SITE START-UP: $2,000 per site Pharmacy, preparation of IRB submission, etc.
![Page 22: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/22.jpg)
Site Agreements
• Caroline Woods at McMaster University
• They will be sent to the PI, contracts office and study coordinator
• Coming soon …
![Page 23: CBMTG 0801 Moving Forward …](https://reader035.vdocuments.mx/reader035/viewer/2022062411/568155f4550346895dc3ba7c/html5/thumbnails/23.jpg)
Questions?